Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
3D Global Biotech Inc. focuses on the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This single active matter is assigned to 1 distinct examiner and 1 distinct art unit, showing a highly concentrated prosecution profile for its current intellectual property efforts. This suggests that the company is prioritizing a specific biotechnological advancement that fits within a narrow technical classification at the patent office.
The busiest examiner for the portfolio is STAVROU, CONSTANTINA E, who is responsible for 1 busiest_examiner_pending action. Because the company only has 1 pending office action, its current progress at the patent office is tied directly to the review and feedback provided by this single examiner. Practitioners should focus on the specific requirements of this examiner, as there are no other pending matters to provide a broader context for how the company's technology is perceived. The use of 1 distinct art unit confirms that the examination is being handled by a single specialized group within the biotechnology division.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STAVROU, CONSTANTINA E | 1 | 43.7% | +36.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18212339 | METHOD FOR THREE-DIMENSIONAL CELL CULTURE USING CELL GROWTH PROMOTING COLLOID AND MASS PRODUCTION OF HIGH-CONCENTRATION EXTRACELLULAR COMPOSITION USING THE SAME | STAVROU, CONSTANTINA E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18212339 | METHOD FOR THREE-DIMENSIONAL CELL CULTURE USING CELL GROWTH PROMOTING COLLOID AND MASS PRODUCTION OF HIGH-CONCENTRATION EXTRACELLULAR COMPOSITION USING THE SAME | STAVROU, CONSTANTINA E | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18212339 | METHOD FOR THREE-DIMENSIONAL CELL CULTURE USING CELL GROWTH PROMOTING COLLOID AND MASS PRODUCTION OF HIGH-CONCENTRATION EXTRACELLULAR COMPOSITION USING THE SAME | STAVROU, CONSTANTINA E | 1632 | §102§103§112 | Final Rejection | — | Pending | Jun 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial